| Name | R306465 |
| Description | R306465 (JNJ-16241199) is an orally active and selective class I histone deacetylase (HDAC 1) inhibitor with an IC50 of 3.3 nM. R306465 has a broad spectrum of antitumor activity, can induce histone 3 acetylation, and induce apoptosis, and can be used to study solid tumors and hematological malignancies. |
| In vitro | b>METHODS: A2780 cells were treated with R306465 (0.1, 0.3, 1 μM, 24-48 h), and FACS analysis was performed to analyze whether the antiproliferative effect in A2780 cells was attributed to the induction of cell cycle arrest or cell death.
RESULTS: R306465 induced apoptosis of A2780 cells in a concentration-dependent manner and inhibited angiogenesis. [2] |
| In vivo | b>METHODS: R306465 (10-40 mpk, oral) was administered subcutaneously to nude mice bearing A2780, H460, and HCT116 cell models, and tumor growth in nude mice was observed.
RESULTS: R306465 inhibited tumor growth in the three nude mouse models. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 5 mg/mL (12.09 mM), Sonication is recommended.
|
| Keywords | R306465 | HDAC1 | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Manganese chloride (tetrahydrate) | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Histone Modification Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Epigenetics Compound Library | ReFRAME Related Library | Hematonosis Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
